Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2026)
Gain Therapeutics (GANX) posted Other Non-Current Assets of $35589.0 for Q2 2026, down 1.37% on a QoQ basis from $36085.0 in Q1 2026, and down 1.9% year-over-year from $36278.0 in Q2 2025.
Powered by 
Analysis
Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Gain Therapeutics has reported Other Non-Current Assets for 7 years, with the latest figure at $35589.0 in Q2 2026.
- On a quarterly basis, Other Non-Current Assets fell 1.9% year-over-year to $35589.0 in Q2 2026; TTM through Jun 2026 was $35589.0, a 1.9% decrease from a year earlier, with the FY2025 full-year figure at $36296.0, up 13.04% from the prior year.
- Other Non-Current Assets was $35589.0 for Q2 2026 at Gain Therapeutics, down from $36085.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $36296.0 in Q4 2025, with the low at $28859.0 in Q3 2022.
- Average Other Non-Current Assets over 5 years is $32833.9, with a median of $31962.5 recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets tumbled 66.83% in 2022, then gained 14.07% in 2025.
- Over 5 years, Other Non-Current Assets stood at $30818.0 in 2022, then rose by 10.39% to $34021.0 in 2023, then retreated by 5.62% to $32109.0 in 2024, then advanced by 13.04% to $36296.0 in 2025, then fell by 1.95% to $35589.0 in 2026.
- The last three Other Non-Current Assets figures came in at $35589.0 (Q2 2026), $36085.0 (Q1 2026), and $36296.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | 35,589.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35,589.00 |
| Mar 31, 2026 | 36,085.00 |
| Dec 31, 2025 | 36,296.00 |
| Sep 30, 2025 | 36,117.00 |
| Jun 30, 2025 | 36,278.00 |
| Mar 31, 2025 | 32,641.00 |
| Dec 31, 2024 | 32,109.00 |
| Sep 30, 2024 | 33,873.00 |
| Jun 30, 2024 | 31,803.00 |
| Mar 31, 2024 | 31,744.00 |
| Dec 31, 2023 | 34,021.00 |
| Sep 30, 2023 | 31,145.00 |
| Jun 30, 2023 | 31,816.00 |
| Mar 31, 2023 | 31,122.00 |
| Dec 31, 2022 | 30,818.00 |
| Sep 30, 2022 | 28,859.00 |
| Jun 30, 2022 | 29,835.00 |
| Mar 31, 2022 | 30,860.00 |
| Dec 31, 2021 | 31,279.00 |
| Sep 30, 2021 | 86,998.00 |